At the start of the COVID-19 pandemic, public health authorities first had to identify and draw attention to common signs and symptoms of the disease.

James Crowe, MD, and members of his lab at Vanderbilt University Medical Center who have pioneered rapid development of monoclonal antibody treatments for life-threatening viral diseases including COVID-19, were featured Sunday on a CBS News 60 Minutes segment titled “The Last Pandemic.”

James Crowe Jr., MD, a physician-scientist on the front lines of global research to eliminate human susceptibility to COVID-19 and other illnesses, is Vanderbilt University’s winner of the 2021 Southeastern Conference Faculty Achievement Award.

On March 15, a new clinic opened at Vanderbilt University Medical Center, the Adult Post-acute COVID Clinic. With no single location, the clinic is a coordinated service across adult general medicine and medical specialty clinics, with a telemedicine component to facilitate initial patient assessments in most cases.

The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.

Vanderbilt University Medical Center is participating in a national phase 1 clinical trial in healthy adults of an investigational vaccine against the B.1.351 variant of the COVID-19 virus that was first identified in South Africa.

Team members serving COVID-19 inpatients were more densely connected, interacting far more than their medical ICU counterparts.